DKSH Bags Pfizer Deal in Cambodia

By Gareth Macdonald contact

- Last updated on GMT

DKSH Bags Pfizer Deal in Cambodia
DKSH Bags Pfizer Deal in Cambodia
DKSH has won a second deal with a Big Pharma firmin Asia in as many months, with US giant Pfizer signing up the firm as its agent in Cambodia.

The deal – financial terms of which were not disclosed – will see DKSH provide marketing, sales and credit management support for Pfizer. The firm has acted as exclusive distributor for the pharmaceutical giant’s drugs in Cambodia since January.

DKSH spokesman Michael Hofer told that Pfizer had been attracted by the firm’s extensive network and the breadth of its offering in the country.

We provide commercial services like brand planning, tender management, promotion, marketing agency, sales, outlet performance management, training, and more.

Thanks to our four branch offices in the commercial centers outside of Phnom Penh [including Battambang, Siem Reap, Kampong, Sihanouk-Ille] we are able cover the entire healthcare market of Cambodia with access to all provinces​.”

Asia growth

The Pfizer deal is the latest in a number of pharmaceutical industry related agreements Asia-focused market services agreements Switzerland-based DKSH has signed in recent months.

In March for example, DKSH signed an extension to its distribution services deal with German manufacturer Bayer​ and last November it agreed to distribute various ingredients used in drug production in Asia on behalf of German chemicals firm Wacker​.

The reason for the flurry of deals in Asia is DKSH’s track record of operating in what for some companies can be challenging markets, according to Hofer.

He said DKSH “is an expert in commercializing healthcare brands across Asia with several thousand sales and marketing specialists, standardized and regionally coordinated processes as well as a strong focus on compliance.”

The firm seems keen to maintain the momentum and is says Hofer currently “looking at opportunities to expand our business partnerships with clients in order to support them in their growth in Asia.”

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q² Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more